Proton pump is the first-line treatment for progression of stomach acids such as peptic ulcer disease, gastroesophageal reflux disease, and nonsteroidal anti-inflammatory drug-induced mucosal damage (Strand, Kim, and Peura 2017). Omeprazole, a proton pump inhibitor, is commonly used to treat gastroesophageal reflux disease, peptic ulcers, and other stomach conditions. OME inhibits H+/Na+ ATPase in the stomach view, ensuring proton secretion of the gastric lumen and reducing gastric acid secretion. Omeprazole's effect temperatures and support have not yet been defined in detail. In addition, prolonged duration of this situation brings with it some side effects (such as gastrointestinal diseases, bone fractures, vitamin and mineral deficiencies) (Fontecha-Barriuso et al. 2020). Therefore, it is of great importance to elucidate the complement in detail for the effectiveness of this transaction process. In our expansion study in this direction, the effectiveness of this pressure on cell viability on fibroblast conditions where Omeprazole was applied in various regions was determined by viability test, while the effectiveness on the expression disruption of apoptotic genes with this pressure was carried out by quantitative real-time PCR analyses. It is aimed to use the additive to better preserve the obtained results of Omeprazole with the data obtained from the analysis results.
Birincil Dil | İngilizce |
---|---|
Konular | Hayvan Hücresi ve Moleküler Biyoloji |
Bölüm | Research Article[En] |
Yazarlar | |
Yayımlanma Tarihi | 23 Temmuz 2024 |
Gönderilme Tarihi | 22 Nisan 2024 |
Kabul Tarihi | 2 Haziran 2024 |
Yayımlandığı Sayı | Yıl 2024 Cilt: 3 Sayı: 1 |